Cite
HARVARD Citation
You, R. et al. (n.d.). Cetuximab or nimotuzumab plus intensity‐modulated radiotherapy versus cisplatin plus intensity‐modulated radiotherapy for stage II‐IVb nasopharyngeal carcinoma. International journal of cancer. 141 (6), pp. 1265-1276. [Online].